298 related articles for article (PubMed ID: 29853659)
1. Diagnosis and Management of Hepatitis in Patients on Checkpoint Blockade.
Reynolds K; Thomas M; Dougan M
Oncologist; 2018 Sep; 23(9):991-997. PubMed ID: 29853659
[TBL] [Abstract][Full Text] [Related]
2. Hepatotoxicity induced by immune checkpoint inhibitors: a comprehensive review including current and alternative management strategies.
Jennings JJ; Mandaliya R; Nakshabandi A; Lewis JH
Expert Opin Drug Metab Toxicol; 2019 Mar; 15(3):231-244. PubMed ID: 30677306
[TBL] [Abstract][Full Text] [Related]
3. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
4. Primary Biliary Cirrhosis and Granulomatous Hepatitis After Immune Checkpoint Blockade in Patients With Metastatic Melanoma: Report of 2 Cases and Literature Discussion.
Ruini C; Haas C; Mastnik S; Knott M; French LE; Schlaak M; Berking C
J Immunother; 2021 Feb-Mar 01; 44(2):71-75. PubMed ID: 33323872
[TBL] [Abstract][Full Text] [Related]
5. Workup and Management of Immune-Mediated Hepatobiliary Pancreatic Toxicities That Develop During Immune Checkpoint Inhibitor Treatment.
Hsu C; Marshall JL; He AR
Oncologist; 2020 Feb; 25(2):105-111. PubMed ID: 32043797
[TBL] [Abstract][Full Text] [Related]
6. Endocrine side effects induced by immune checkpoint inhibitors.
Corsello SM; Barnabei A; Marchetti P; De Vecchis L; Salvatori R; Torino F
J Clin Endocrinol Metab; 2013 Apr; 98(4):1361-75. PubMed ID: 23471977
[TBL] [Abstract][Full Text] [Related]
7. When steroids are not enough in immune-related hepatitis: current clinical challenges discussed on the basis of a case report.
Ziogas DC; Gkoufa A; Cholongitas E; Diamantopoulos P; Anastasopoulou A; Ascierto PA; Gogas H
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33144335
[TBL] [Abstract][Full Text] [Related]
8. Success of immune checkpoint blockade therapies - mechanisms and implications for hepatology.
Bengsch B; Thimme R
Z Gastroenterol; 2019 Jan; 57(1):74-86. PubMed ID: 30641606
[TBL] [Abstract][Full Text] [Related]
9. Optimal management of immune-related adverse events resulting from treatment with immune checkpoint inhibitors: a review and update.
Nagai H; Muto M
Int J Clin Oncol; 2018 Jun; 23(3):410-420. PubMed ID: 29516216
[TBL] [Abstract][Full Text] [Related]
10. Checkpoint inhibitor hepatotoxicity: pathogenesis and management.
Cunningham M; Gupta R; Butler M
Hepatology; 2024 Jan; 79(1):198-212. PubMed ID: 36633259
[TBL] [Abstract][Full Text] [Related]
11. PD-1 checkpoint inhibition: Toxicities and management.
Hahn AW; Gill DM; Agarwal N; Maughan BL
Urol Oncol; 2017 Dec; 35(12):701-707. PubMed ID: 28889921
[TBL] [Abstract][Full Text] [Related]
12. Gastrointestinal and Hepatic Complications of Immunotherapy: Current Management and Future Perspectives.
Dougan M
Curr Gastroenterol Rep; 2020 Mar; 22(4):15. PubMed ID: 32185493
[TBL] [Abstract][Full Text] [Related]
13. Checkpoint Blockade Toxicity and Immune Homeostasis in the Gastrointestinal Tract.
Dougan M
Front Immunol; 2017; 8():1547. PubMed ID: 29230210
[TBL] [Abstract][Full Text] [Related]
14. Immune-related adverse events with immune checkpoint blockade: a comprehensive review.
Michot JM; Bigenwald C; Champiat S; Collins M; Carbonnel F; Postel-Vinay S; Berdelou A; Varga A; Bahleda R; Hollebecque A; Massard C; Fuerea A; Ribrag V; Gazzah A; Armand JP; Amellal N; Angevin E; Noel N; Boutros C; Mateus C; Robert C; Soria JC; Marabelle A; Lambotte O
Eur J Cancer; 2016 Feb; 54():139-148. PubMed ID: 26765102
[TBL] [Abstract][Full Text] [Related]
15. [Toxicity of immune checkpoints inhibitors].
Delaunay M; Caron P; Sibaud V; Godillot C; Collot S; Milia J; Prévot G; Mazières J
Rev Mal Respir; 2018 Dec; 35(10):1028-1038. PubMed ID: 30213624
[TBL] [Abstract][Full Text] [Related]
16. Hepatotoxicity of immune checkpoint inhibitors: An evolving picture of risk associated with a vital class of immunotherapy agents.
Suzman DL; Pelosof L; Rosenberg A; Avigan MI
Liver Int; 2018 Jun; 38(6):976-987. PubMed ID: 29603856
[TBL] [Abstract][Full Text] [Related]
17. Cutaneous Adverse Events of Immune Checkpoint Inhibitors: A Summarized Overview.
Plachouri KM; Vryzaki E; Georgiou S
Curr Drug Saf; 2019; 14(1):14-20. PubMed ID: 30058498
[TBL] [Abstract][Full Text] [Related]
18. Combined Radiation Therapy and Immune Checkpoint Blockade Therapy for Breast Cancer.
Hu ZI; Ho AY; McArthur HL
Int J Radiat Oncol Biol Phys; 2017 Sep; 99(1):153-164. PubMed ID: 28816141
[TBL] [Abstract][Full Text] [Related]
19. Dermatologic Reactions to Immune Checkpoint Inhibitors : Skin Toxicities and Immunotherapy.
Sibaud V
Am J Clin Dermatol; 2018 Jun; 19(3):345-361. PubMed ID: 29256113
[TBL] [Abstract][Full Text] [Related]
20. Erythema nodosum-like panniculitis mimicking disease recurrence: A novel toxicity from immune checkpoint blockade therapy-Report of 2 patients.
Tetzlaff MT; Jazaeri AA; Torres-Cabala CA; Korivi BR; Landon GA; Nagarajan P; Choksi A; Chen L; Uemura M; Aung PP; Diab A; Sharma P; Davies MA; Amaria R; Prieto VG; Curry JL
J Cutan Pathol; 2017 Dec; 44(12):1080-1086. PubMed ID: 28901560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]